Abstract | PURPOSE: DESIGN: Retrospective consecutive observational cohort study. METHODS: Thirty-one eyes of 31 consecutive highly myopic patients with CNV and showing a subretinal hyperreflective exudation on SD OCT were included. Morphologic changes were assessed before and after anti- VEGF therapy, based on the subretinal hyperreflective exudation thickness, retinal thickness at the level of the CNV, and central macular thickness. RESULTS: After anti- VEGF treatment (mean follow-up of 1.9 ± 0.8 months, mean number of injections 1.8 ± 0.6), the subretinal hyperreflective exudation regressed completely in 29 of 31 eyes (93.5%) and partially in 2 of 31 eyes (6.5%). Mean subretinal hyperreflective exudation thickness, mean retinal thickness at the level of the CNV, and mean central macular thickness significantly decreased from 102 ± 50 μm to 2.6 ± 10.2 μm (P < .0001), from 419 ± 99 μm to 312 ± 64 μm (P < .0001), and from 361 ± 69 μm to 326 ± 72 μm (P = .0008), respectively. CONCLUSION: The subretinal hyperreflective exudation was an SD OCT finding that correlated with signs of active myopic CNV (either subretinal fluid/intraretinal cysts on SD OCT or dye leakage on fluorescein angiography) and responded to treatment with anti- VEGF agents. The presence of a subretinal hyperreflective exudation on SD OCT could help in making decisions on the need to perform or not perform fluorescein angiography, and regarding treatment or retreatment.
|
Authors | Elsa Bruyère, Violaine Caillaux, Salomon Yves Cohen, David Martiano, Raphaelle Ores, Nathalie Puche, Eric H Souied |
Journal | American journal of ophthalmology
(Am J Ophthalmol)
Vol. 160
Issue 4
Pg. 749-58.e1
(Oct 2015)
ISSN: 1879-1891 [Electronic] United States |
PMID | 26164828
(Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Chemical References |
- Angiogenesis Inhibitors
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
|
Topics |
- Aged
- Angiogenesis Inhibitors
(therapeutic use)
- Blood-Retinal Barrier
- Capillary Permeability
- Choroidal Neovascularization
(diagnosis, drug therapy, physiopathology)
- Female
- Fluorescein Angiography
- Humans
- Intravitreal Injections
- Male
- Middle Aged
- Myopia, Degenerative
(diagnosis, drug therapy, physiopathology)
- Retrospective Studies
- Subretinal Fluid
(physiology)
- Tomography, Optical Coherence
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
|